Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DMT, DOx series, escaline show less
Proscaline
3,5-dimethoxy-4-propoxyphenethylamine
Proscaline (3,5-dimethoxy-4-propoxyphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is a close structural relative of mescaline, but substantially more potent per milligram.[1] It activates serotonin receptors in the brain, producing the altered perception and emotional shifts characteristic of classical psychedelics.[2]
Proscaline (3,5-dimethoxy-4-propoxyphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is the 4-propyloxy homolog of mescaline, distinguished by substantially greater potency per milligram.[1] Proscaline is a presumed 5-HT₂A receptor agonist, producing its effects by disrupting serotonin-mediated sensory filtering in the cortex.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DMT, DOx series, escaline show less
Czechoslovakian researchers first tested proscaline at doses up to 80 mg, noting effects lasting beyond 12 hours.[3] Alexander Shulgin independently synthesized it and published detailed self-experiments as entry #140 in PiHKAL (1991).[4] Today it circulates in small quantities among research chemical users and remains unscheduled by name in most countries.
Subjective effects include physical warmth, deep bodily relaxation, euphoria, and emotional contentment. The experience is defined by its somatic quality — sustained bodily ease and emotional equanimity with little visual activity at common doses.[3] At higher doses, warmth can shift into irritability, and residual dream disturbances are reported.
Proscaline does not cause physical dependence; tolerance builds rapidly through serotonin downregulation, making compulsive use self-limiting.[5] The primary risks are psychological — panic, anxiety, and psychosis-like states — amplified by high doses and by combining with monoamine oxidase inhibitors, which can trigger dangerous serotonin overload.[6] Evidence comes almost entirely from one mouse study and Shulgin's self-experiments — human safety data are essentially absent.[1]
History[edit]
Discovery
Czechoslovakian researchers first tested proscaline at doses up to 80 mg, observing effects lasting beyond 12 hours and residual dream disturbances.[3] Their identities remain unrecorded in indexed literature. Alexander Shulgin independently synthesized it and documented it as compound #140 in PiHKAL (1991), describing somatic warmth, euphoria, and minimal visual effects at 30–60 mg.[4][3]
Clinical and cultural significance
The only peer-reviewed study — Halberstadt et al. (2019) — confirmed proscaline is more potent than mescaline and escaline in a mouse behavioral assay.[1] No clinical trials have been conducted and the compound has not entered pharmaceutical development.
Prohibition and modern use
The United Kingdom classified proscaline as a Class A substance under the Misuse of Drugs Act 1971, using a broad clause covering ring-alkoxy phenethylamine derivatives.[7] No other jurisdiction has individually scheduled it by name. Proscaline appeared on research chemical markets during the 2000s–2010s expansion of novel psychoactive substances, though no forensic seizure case reports have been published.
Proscaline takes its name from its position in the "scaline" series — a family of mescaline homologues named by extending the parent compound's suffix. The series is defined by progressive lengthening of mescaline's 4-methoxy group into longer alkoxy chains: Escaline (ethoxy), proscaline (n-propoxy), and isoproscaline (isopropoxy). The naming convention reflects systematic chemical relationship rather than any cultural or traditional identity.
Chemistry[edit]
Structural class
Proscaline belongs to the "scaline" series — a family of mescaline homologues defined by progressively longer alkoxy chains at the 4-position of the ring.
Where escaline carries 4-ethoxy, proscaline carries 4-n-propoxy. The related compound 3C-P shares the same ring substitution but adds a methyl group to the side chain, making it more potent.[8]
Molecular structure
| Molecular formula | C₁₃H₂₁NO₃ |
| Molecular weight | 239.31 g/mol |
Proscaline hydrochloride is a white solid with a melting point of 170–172 °C.[4][3]
Pharmacology[edit]
Mechanism of action
Proscaline activates serotonin receptors in the cortex.[1][9] This is established behaviorally: proscaline reliably produces the mouse head-twitch response, a behavior driven exclusively by serotonin receptor activation and blocked by selective antagonists. Activation of these receptors on deep-layer cortical neurons is the established mechanism for psychedelic effects across this compound class.[2]
No receptor binding data have been published for proscaline — no affinities, potency values, or selectivity profiles. The mechanism is inferred from structural class membership and behavioral assay results.[1]
Pharmacokinetics
No human pharmacokinetic data exist for proscaline. Based on mescaline, the closest well-studied relative, oral absorption peaks around 2 hours, plasma half-life is approximately 3.5 hours, and subjective effects last 6–14 hours depending on dose.[6]inferred The body is expected to break proscaline down through pathways similar to mescaline — including one mediated by the enzyme MAO-A, which is blocked by MAOI drugs, and which would sharply raise proscaline's levels if inhibited.[10][11]inferred
Neuroscience[edit]
Where it acts
Proscaline is expected to engage the same brain circuits as mescaline, psilocybin, and LSD — serotonin receptors concentrated on deep-layer neurons of the prefrontal cortex.[2]inferred Activating these neurons disrupts normal sensory filtering and raises overall brain activity, producing the characteristic altered state.
Why proscaline skews more somatic and less visual than mescaline at standard doses is not known. It may reflect dosing below the visual activation threshold, or a subtly different pattern of brain engagement — no data exists to settle the question.
Why it matters
The leading framework for psychedelic action — REBUS — proposes that these drugs relax the brain's top-down predictions, allowing suppressed sensory and emotional content to surface. Serotonergic psychedelics also promote new connections between brain cells through growth factor signaling. Both ideas are built primarily from LSD and psilocybin data; whether they explain proscaline's somatic-emotional profile is plausible but untested — no direct neuroplasticity data exist for proscaline.
- Does proscaline's somatic, visual-sparse phenomenology reflect a distinctive receptor activation profile, or does it simply reflect insufficient dose relative to the visual threshold?
- Does the 4-propoxy group confer different signaling bias relative to mescaline's 4-methoxy?
- Does proscaline promote structural neuroplasticity, and at what concentrations relative to mescaline?
Subjective Effects[edit]
Proscaline's experience is defined by the body, not the eye. Sustained physical warmth, deep muscle relaxation, and emotional contentment settle in and hold — visual activity is minimal at common doses. Set and setting shape the emotional tone strongly; that warmth can shift toward irritability as dose increases.
Within the scaline family, proscaline sits at roughly 5–10× mescaline's potency by weight but with a qualitatively different character. Where mescaline produces broad visual psychedelia across its active range, proscaline skews toward the somatic and emotional — visuals emerge only at the upper dose boundary.
First investigated by Czechoslovakian researchers at doses up to 80 mg, proscaline was independently synthesized and documented by Alexander Shulgin as entry #140 in PiHKAL (1991).[3] A single peer-reviewed study — a 2019 mouse behavioral assay — confirmed its greater potency relative to mescaline, but no clinical trials or binding studies have followed.[1] It remains unscheduled by name in most jurisdictions and circulates in small quantities among research chemical users.
Subjective effects include physical relaxation, euphoria, emotional warmth, and deep contentment. The experience is defined by its somatic emphasis — a sustained bodily warmth and emotional equanimity with minimal visual phenomena at common doses, distinguishing it from the broad-spectrum psychedelia of mescaline.[4] Irritability at higher doses and residual dream disturbances are reported unsought effects.
Proscaline produces no physical dependence; rapid tolerance through 5-HT₂A downregulation makes compulsive redosing self-limiting.[5] The primary risks are psychological — anxiety, panic, and transient psychosis-like states — amplified by high doses, predisposition, and unfavorable setting.[6] No clinical trials, receptor binding data, or human pharmacokinetic studies have been published; the evidence base rests on one mouse behavioral study and Shulgin's self-experiments.
History[edit]
Discovery
The earliest documented investigation of proscaline originates from Czechoslovakian researchers who tested the compound at doses up to 80 mg, observing residual dream disturbances and effects extending beyond 12 hours.[4] The specific investigators remain unidentified in indexed literature; the work is known only through Shulgin's reference. Alexander Shulgin independently synthesized proscaline and documented it as compound #140 in PiHKAL (1991),[3] characterizing it through self-experiments at 30–60 mg as primarily somatic and emotional — notable euphoria and contentment, with minimal visual phenomena.[4]
Clinical and cultural significance
Proscaline has received almost no formal pharmacological investigation. The sole peer-reviewed study — Halberstadt et al. (2019) — measured its behavioral potency in the mouse head-twitch response assay as part of a broader structure-activity investigation of mescaline analogs, confirming greater potency than both Mescaline and escaline.[1] No clinical trials have been registered, and the compound has not entered pharmaceutical development.
Prohibition and modern use
The United Kingdom classified proscaline as a Class A substance from the inception of the Misuse of Drugs Act 1971, under a generic phenethylamine clause covering ring-alkoxy-substituted derivatives.[7] No other jurisdiction has individually scheduled it by name. Proscaline appeared on research chemical markets during the broader expansion of novel psychoactive substances in the 2000s–2010s, though no forensic seizure case reports have been published.
Proscaline takes its name from its position in the "scaline" series — a family of mescaline homologues named by extending the parent compound's suffix. The series is defined by progressive lengthening of mescaline's 4-methoxy group into longer alkoxy chains: Escaline (ethoxy), proscaline (n-propoxy), and isoproscaline (isopropoxy). The naming convention reflects the systematic chemical relationship rather than any cultural or traditional identity.
Chemistry[edit]
Structural class
Proscaline belongs to the "scaline" series of psychedelic phenethylamines — 3,5-dimethoxy-4-alkoxyphenethylamines derived from mescaline by progressive lengthening of the 4-position alkoxy group. Where mescaline carries a 4-methoxy group, escaline substitutes 4-ethoxy, and proscaline substitutes 4-n-propoxy. The molecule is achiral, with no stereochemical complexity.
The α-methyl (amphetamine) homolog of proscaline is 3C-P, which shares the same ring substitution pattern but adds a methyl group on the side chain α-carbon, conferring increased potency at 5-HT₂A-mediated signaling pathways.[8]
Molecular structure
| Molecular formula | C₁₃H₂₁NO₃ |
| Molecular weight | 239.31 g/mol |
The molecule consists of a phenethylamine backbone with three ring substituents: 3-methoxy, 4-n-propoxy, and 5-methoxy. The 4-propoxy group — a three-carbon alkyl ether chain — is the structural feature that distinguishes proscaline from mescaline (4-methoxy) and escaline (4-ethoxy).
Physical properties
Proscaline hydrochloride crystallizes as a white solid with a melting point of 170–172 °C.[3][4] Solubility, stability, and degradation pathways have not been formally characterized.
Pharmacology[edit]
Mechanism of action
Proscaline acts as a serotonin 5-HT₂A receptor agonist. This is established by its structural class — a 3,4,5-trisubstituted phenethylamine — and confirmed behaviorally: proscaline reliably elicits the mouse head-twitch response, a behavior mediated exclusively by 5-HT₂A activation and abolished by selective antagonists.[1][9]
Activation of 5-HT₂A receptors on deep-layer cortical pyramidal neurons is the established mechanism for psychedelic effects in this compound class.[2] Conformational mobility of the 3- and 5-methoxy groups is required for receptor activation in the 3,4,5-substituted series, as conformationally restricted analogs lose activity.[10]
No receptor binding data — binding affinities, potency values, or selectivity profiles — have been published for proscaline. By structural analogy with mescaline, secondary interactions at other receptor targets may occur, but 5-HT₂A agonism is the principal driver of psychedelic effects.
Pharmacokinetics
No human pharmacokinetic data exist for proscaline. The following parameters are inferred from Mescaline, the closest well-characterized parent compound.inferred
In a controlled human study, oral mescaline showed dose-proportional pharmacokinetics across 100–800 mg, reaching peak plasma concentration in approximately 2 hours, with a plasma half-life of approximately 3.5 hours and subjective effects lasting 6–14 hours depending on dose.[6]
Mescaline undergoes three principal metabolic transformations: acetylation, demethylation, and oxidative deamination (the last mediated by MAO-A).[11][12] Proscaline would be expected to undergo similar pathways, with depropylation as an additional route. The MAO-A-mediated deamination pathway implies vulnerability to MAOI interactions.inferred
Neuroscience[edit]
Where it acts
As a serotonin 2A receptor agonist, proscaline is expected to engage the same cortical circuits as mescaline, psilocybin, and LSD.inferred These receptors are concentrated on deep-layer pyramidal neurons of the prefrontal cortex.[2] Activation increases glutamate transmission, disrupts default mode network coherence, reduces thalamocortical gating, and raises global neural entropy — the established correlates of the serotonergic psychedelic state.
Whether proscaline's reportedly somatic-dominant, visual-sparse character at standard doses reflects a distinctive neural activation pattern — potentially engaging somatosensory or interoceptive cortex preferentially — or simply falls below the dose threshold for robust visual cortex engagement remains unknown.
Why it matters
The REBUS model proposes that psychedelics relax the precision of high-level predictions in cortical hierarchies, allowing suppressed sensory and emotional content to surface. Serotonergic psychedelics also promote structural neuroplasticity through BDNF and mTOR signaling pathways. Both frameworks were developed primarily from LSD and psilocybin data — their applicability to proscaline's somatic-emotional phenomenology is untested but plausible given shared receptor pharmacology. No direct neuroplasticity data exist for proscaline.
- Does proscaline's somatic, visual-sparse phenomenology reflect a distinctive receptor activation profile, or does it simply reflect insufficient dose relative to the visual threshold?
- Does the 4-propoxy group confer different signaling bias relative to mescaline's 4-methoxy?
- Does proscaline promote structural neuroplasticity, and at what concentrations relative to mescaline?
Subjective Effects[edit]
Proscaline's experiential character is unusual among phenethylamine psychedelics. At common doses, physical warmth, bodily relaxation, and emotional contentment dominate — the kind of deep somatic satisfaction that distinguishes this compound from the visual complexity typical of mescaline or the 2C series. Set and setting exert significant influence on emotional valence; at higher doses, affective warmth can shift toward irritability, and psychological vulnerability amplifies adverse outcomes.
Within the scaline series, proscaline sits at roughly 5–10× mescaline's potency by weight but with a qualitatively different character. Where mescaline produces broad-spectrum psychedelia across its active range, proscaline at equivalent relative doses skews toward the somatic and emotional, with visual effects emerging only at the upper dose boundary.
Effect Grid
At common doses (30–40 mg oral), proscaline's characteristic profile fully manifests: deep contentment, emotional warmth, euphoria, and a somatic quality that distinguishes it from more visually oriented psychedelics. Shulgin described 40 mg as producing "deep feeling of peace and contentment" lasting throughout the day. Cognitive effects include enhanced novelty perception and conceptual thinking, while visual phenomena remain notably mild or absent at this range.
Physically, spontaneous body sensations become more pronounced — warmth, tingling, and a sense of physical well-being. Pupil dilation is expected. Nausea is not prominently reported.
Duration is 8–12 hours. Sleep is unlikely during the active phase. Plan for a full day commitment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Symmetrical texture repetition · Brightness alteration · Visual breathing · Music enhancement · Environmental patterning · Depth perception distortion · Perspective distortion · Tracers · After-images · Light sensitivity · Sound sensitivity · Visual morphing · Auditory enhancement · Visual acuity enhancement · Holotropic state · Visual diffraction · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual melting · Object transformations · Environmental orbism / cubism · Object activation · Visual recursion · Internal hallucinations · External hallucinations · Auditory hallucinations
Environmental patterning · Depth perception distortion · Perspective distortion · Tracers · After-images · Light sensitivity · Sound sensitivity · Visual morphing · Auditory enhancement · Visual acuity enhancement · Holotropic state · Visual diffraction · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual melting · Object transformations · Environmental orbism / cubism · Object activation · Visual recursion · Internal hallucinations · External hallucinations · Auditory hallucinations
Spontaneous body sensations · Nausea · Dizziness · Insomnia · Stimulation · Tingling / electric sensations · Restlessness · Appetite suppression · Bodily pressures · Dry mouth · Laughter fits · Tactile euphoria · Vibrations / buzzing · Muscle tension · Bodily heaviness · Bodily lightness · Body schema distortion · Breathing alteration · Excessive sweating · Headache · Heart rate perception changes · Vasoconstriction · Nystagmus (eye wobbles) · Abnormal heartbeat · Trembling · Vomiting · Bruxism · Bodily dissociation
Insomnia · Stimulation · Tingling / electric sensations · Restlessness · Appetite suppression · Bodily pressures · Dry mouth · Laughter fits · Tactile euphoria · Vibrations / buzzing · Muscle tension · Bodily heaviness · Bodily lightness · Body schema distortion · Breathing alteration · Excessive sweating · Headache · Heart rate perception changes · Nystagmus (eye wobbles) · Abnormal heartbeat · Trembling · Vomiting · Bruxism · Bodily dissociation
Aesthetic enhancement · Introspection enhancement · Openness enhancement · Thought connectivity · Cognitive euphoria · Immersion enhancement · Cognitive flexibility · Increased nature relatedness · Multiple thought streams · Thought acceleration · Creativity enhancement · Memory suppression · Thought loops · Cognitive impairment · Focus suppression · Analysis enhancement · Humor enhancement · Confusion · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Delusions
Thought connectivity · Cognitive euphoria · Immersion enhancement · Cognitive flexibility · Increased nature relatedness · Multiple thought streams · Thought acceleration · Creativity enhancement · Memory suppression · Thought loops · Cognitive impairment · Focus suppression · Analysis enhancement · Humor enhancement · Confusion · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization
Anxiety · Empathy enhancement · Catharsis · Dysphoria
Derealization · Sociability enhancement · Trust enhancement · Flow state · Boundary dissolution · Identity alteration · Ego dissolution
Boundary dissolution · Identity alteration · Ego dissolution
Recursive awareness
Timeline
First alerts appear as subtle shifts in bodily awareness — a faint tingling, mild sensory sharpening, or gentle warmth. Effects are easily overlooked at lower doses.
Physical and emotional effects build steadily. Somatic warmth deepens, mood elevation becomes distinct, and a growing sense of relaxation or restlessness (variable by individual) develops.
Maximum intensity of somatic and emotional effects. Deep contentment, euphoria, and physical well-being dominate. Visual phenomena remain subdued relative to other phenethylamine psychedelics at common doses.
Effects sustain at a diminished but still present intensity. Emotional warmth and physical relaxation persist. Cognitive clarity typically returns before somatic effects fully resolve.
Gradual return toward baseline. Residual warmth, mild mood elevation, and gentle fatigue are common. Physical effects dissipate before emotional tone fully normalizes.
Residual calm, mild reflectiveness, and possible sleep difficulty persist for several hours after subjective effects resolve. At higher doses (80 mg), dream disturbances may extend into the following night.
⚠ Do not drive or operate heavy machinery for the remainder of the day following ingestion.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No toxicity studies of any kind have been published for proscaline in any species.safety citation needed The mescaline class has a wide safety margin in animal models, but this cannot be applied directly to proscaline, which differs in potency and how it moves through the body. The absence of adverse event reports reflects a data gap, not a demonstrated safety record.
Heart and circulation
Serotonin receptor activation raises heart rate and blood pressure — confirmed for mescaline in controlled human studies.[6] Proscaline is expected to share this cardiovascular profile. No proscaline-specific data exist.
Nausea
Nausea and vomiting are common dose-dependent effects with mescaline.[6] Shulgin's proscaline accounts do not prominently mention nausea,[3] but the sample is far too small to estimate how common it is.
Psychological risks
Anxiety, panic, paranoia, and brief psychosis-like states can occur with any serotonin receptor agonist psychedelic — especially at high doses, in psychologically vulnerable individuals, or in unfavorable settings. Persistent visual disturbances after the experience — HPPD, where visual artifacts outlast the drug — are documented for this compound class;[12] the specific risk for proscaline is unknown.
Tolerance and dependence
Proscaline does not produce physical dependence or a withdrawal. Tolerance develops rapidly through serotonin downregulation, apparent within 24 hours of a single dose.[5]
Full cross-tolerance exists with other serotonergic psychedelics: LSD, psilocybin, Mescaline, and DMT.[5][9] No cross-tolerance occurs with ketamine, MDMA, or cannabinoids.
Drug Interactions
All interaction data are inferred from mescaline class pharmacology. MAO inhibitors carry the highest risk — MAO-A normally breaks down phenethylamines, so blocking it with pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) or botanical sources (harmine and harmaline in ayahuasca or Peganum harmala) would sharply increase proscaline's levels and risk dangerous serotonin overload.[10][11]safety citation needed
Lithium combined with serotonergic psychedelics carries seizure risk — this combination is contraindicated.safety citation needed Cannabis intensifies and unpredictably alters the experience, raising anxiety risk. Stimulants (amphetamines, cocaine) add cardiovascular stress on top of proscaline's own effects. 5-HT₂A antagonists (ketanserin, risperidone, clozapine) reduce or block the psychedelic effect.[6]
Contraindications
6 knownPersonal or family history of psychotic disorders, schizophrenia spectrum conditions, or bipolar I disorder is an absolute contraindication — serotonin receptor activation can trigger or worsen psychotic episodes. Concurrent MAOI use is contraindicated due to serotonin overload risk.safety citation needed Lithium is contraindicated due to seizure risk.safety citation needed
Significant cardiovascular disease — uncontrolled high blood pressure, recent heart attack, serious irregular heartbeat — is a relative contraindication given expected effects on heart rate and blood pressure.[6] Pregnancy is a contraindication; no reproductive safety data exist for proscaline or mescaline.
Harm Reduction[edit]
Forms & Identification
Proscaline circulates primarily as a white crystalline powder (hydrochloride salt), though pressed pills and capsules may appear on research chemical markets. It is visually indistinguishable from dozens of other white-powder phenethylamines, including far more potent compounds from the NBOMe or DOx series.
Reagent testing narrows the field but cannot confirm identity with certainty; laboratory analysis is the only definitive method. Given proscaline's rarity, the risk of receiving a mislabeled substitute is substantial.
Guidelines
- Test every batch with at least two reagent kits before use; do not rely on vendor labeling alone.
- Start at the low end of the reported active range and wait at least 3 hours before considering redosing — onset can be slow and plateau effects may build gradually.
- Eat a light meal 2–3 hours before dosing to reduce nausea risk without slowing absorption excessively.
- Have a sober, trusted companion present for the full duration, particularly for first experiences or unfamiliar batches.
- Prepare the physical environment in advance: comfortable temperature, accessible water and light snacks, minimal stimulation, and a quiet space to retreat to if the experience becomes overwhelming.
- Keep a written note of substance name, dose, and time of ingestion visible — useful for the sitter and essential if emergency services are needed.
Set & Setting
Proscaline's 8–12 hour duration demands deliberate preparation. The full day should be free of obligations — fatigue or time pressure during the extended tail increases the likelihood of anxiety and irritability.
Emotional state before dosing shapes the experience. Proscaline's somatic-emotional character amplifies both positive and negative states: warmth and contentment in favorable conditions, irritability and distress in unfavorable ones. A calm, familiar, private environment with a trusted sober companion is strongly recommended, especially given the compound's limited human data.
Aftercare & integration. The extended duration of proscaline means residual effects — emotional sensitivity, mild fatigue, altered dream patterns — may persist into the following day. Plan for a low-demand recovery day. Sleep may be disrupted the first night; this is expected and typically resolves without intervention.
Journaling or discussing the experience with a trusted person within the first few days helps consolidate insights and process difficult material. If distressing psychological content surfaces during the experience, integration-oriented therapy with a practitioner experienced in psychedelic contexts can be valuable. Persistent anxiety, depersonalization, or visual disturbances beyond a few days warrant professional consultation.
Recovery & Support
Proscaline does not produce physical dependence or withdrawal. However, repeated use of any psychedelic can become a pattern of avoidance or self-medication for underlying psychological distress. If psychedelic use is becoming compulsive, escalating, or interfering with daily functioning, support is available.
Peer support communities, harm reduction organizations, and therapists specializing in psychedelic integration can help. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free peer support for people during or after psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety and transient confusion during a psychedelic experience are distressing but not emergencies. Seek immediate help if any of the following occur: chest pain or pounding heartbeat that does not subside, seizure activity, loss of consciousness, sustained panic with self-harm risk, or complete disconnection from reality with inability to recognize surroundings or people.
Immediate steps:
- Stay with the person. Speak calmly and simply.
- Move them to a quiet, low-stimulation environment if possible.
- If unconscious, place in the recovery position (on their side, airway clear).
- Call emergency services if symptoms are severe, worsening, or involve chest pain, seizure, or loss of consciousness.
- Do not restrain the person unless they are in immediate physical danger.
- Do not induce vomiting.
What to tell the dispatcher: Name the substance (proscaline, a psychedelic phenethylamine), the dose if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Proscaline is not individually scheduled by name in most national drug control frameworks, but may be captured by structural analog provisions or generic phenethylamine clauses. Legal status should be verified independently for any specific jurisdiction.
Legal status changes frequently and varies by jurisdiction. This article does not constitute legal advice.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A (Schedule 1) | Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(c): generic clause covering phenethylamine derivatives with ring alkoxy substitution[7] |
| United States | Not specifically scheduled (federal) | Mescaline is Schedule I (CSA). Proscaline is not individually listed. The Federal Analogue Act (21 U.S.C. §813) may apply if intended for human consumption, given structural similarity to mescaline |
| Canada | Not specifically scheduled | Mescaline is Schedule III (CDSA). Proscaline is not individually listed in the Controlled Drugs and Substances Act schedules |
| Australia | Uncertain | Mescaline is Schedule 9 (Prohibited Substance) under the Poisons Standard. Proscaline may be covered by analogue provisions but is not explicitly listed |
| Germany | Likely controlled | The Neue-psychoaktive-Stoffe-Gesetz (NpSG, 2016) uses structural analogue definitions that may cover proscaline[13] |
| Switzerland / Austria | Likely controlled | Phenethylamine analog scheduling provisions may capture proscaline under structural definitions[13] |
Analogue act considerations
In the United States, prosecution under the Federal Analogue Act requires demonstrating that proscaline is "substantially similar" in chemical structure and pharmacological effect to a Schedule I or II substance. Proscaline's direct structural derivation from mescaline and its confirmed serotonin receptor activity[1] would likely satisfy both criteria. No published case law specifically addresses proscaline.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No controlled toxicity studies, lethal dose data, or organ toxicity assessments have been published for proscaline in any species.safety citation needed The mescaline class carries a large therapeutic index in animal models, but this cannot be quantitatively extrapolated to proscaline, which differs in potency and lipophilicity. The absence of adverse event reports reflects a data gap — not a demonstrated safety record.
Heart and circulation
5-HT₂A agonism produces dose-dependent increases in heart rate and blood pressure, confirmed for mescaline in controlled human studies.[6] Proscaline is expected to share this cardiovascular profile. No proscaline-specific heart or circulation data exist.
Nausea
Nausea and vomiting are common dose-dependent effects of mescaline.[6] Shulgin's proscaline reports do not prominently mention nausea,[4] but the sample size is far too small to estimate incidence.
Psychological risks
Anxiety, panic, paranoia, and transient psychosis-like states can occur with any 5-HT₂A agonist psychedelic, particularly at high doses, in psychologically vulnerable individuals, or in unfavorable settings. No proscaline-specific incidence data are available.
Hallucinogen Persisting Perception Disorder (HPPD) — persistent visual disturbances following psychedelic use — is documented for the 5-HT₂A agonist class.[13] The risk for proscaline specifically is unknown.
Tolerance and dependence
Proscaline is not considered habit-forming. Tolerance develops rapidly through 5-HT₂A downregulation, a mechanism demonstrated for the agonist class and apparent within 24 hours of a single dose.[5]
Full cross-tolerance exists with other serotonergic psychedelics, including LSD, psilocybin, Mescaline, and DMT.[5][9] No cross-tolerance occurs with ketamine, MDMA, or cannabinoids. The mescaline class lacks significant activation of dopamine reward pathways, and no withdrawal has been documented.
Drug Interactions
All interaction data are inferred from mescaline class pharmacology. No proscaline-specific drug interaction studies have been published.
MAO inhibitors represent the highest-risk interaction. MAO-A mediates the breakdown of phenethylamines including mescaline.[11][12] Co-administration of monoamine oxidase inhibitors — pharmaceutical (phenelzine, tranylcypromine, moclobemide) or botanical (harmine/harmaline in ayahuasca preparations, Peganum harmala) — would be expected to markedly increase proscaline levels and elevate the risk of serotonin syndrome.safety citation needed
5-HT₂A antagonists (ketanserin, risperidone, clozapine) reduce or block the psychedelic effects of mescaline-class compounds.[6]
Lithium combined with serotonergic psychedelics has been associated with seizure risk across the psychedelic class. This combination should be considered contraindicated.safety citation needed
Cannabis intensifies and unpredictably alters psychedelic experiences, with increased anxiety risk. Stimulants (amphetamines, cocaine) produce additive cardiovascular stress with 5-HT₂A agonist phenethylamines.
Contraindications
6 knownPersonal or family history of psychotic disorders, schizophrenia spectrum conditions, or bipolar I disorder is an absolute contraindication for all 5-HT₂A agonist psychedelics, including proscaline. These conditions involve dysregulated serotonergic signaling; 5-HT₂A agonism can trigger or worsen psychotic episodes.
Concurrent MAOI use is contraindicated due to serotonin syndrome risk and unpredictable potentiation.safety citation needed Concurrent lithium use is contraindicated due to seizure risk.safety citation needed
Significant heart disease — uncontrolled high blood pressure, recent heart attack, clinically significant irregular heartbeat — is a relative contraindication given the expected cardiovascular effects of 5-HT₂A agonist phenethylamines.[6]
Pregnancy is a contraindication. No reproductive toxicity data exist for proscaline or mescaline; the precautionary principle applies.
Harm Reduction[edit]
Forms & Identification
Proscaline circulates primarily as a white crystalline powder (hydrochloride salt), though pressed pills and capsules may appear on research chemical markets. Because it is visually indistinguishable from dozens of other white-powder phenethylamines — including far more potent compounds like members of the NBOMe or DOx series — visual identification alone is unreliable. Reagent testing narrows the field but cannot confirm identity with certainty; laboratory analysis is the only definitive method. Given proscaline's rarity, the risk of receiving a mislabeled substitute is substantial.
Guidelines
- Test every batch with at least two reagent kits before use; do not rely on vendor labeling alone.
- Start at the low end of the reported active range and wait at least 3 hours before considering redosing — onset can be slow and plateau effects may build gradually.
- Eat a light meal 2–3 hours before dosing to reduce nausea risk without slowing absorption excessively.
- Have a sober, trusted companion present for the full duration, particularly for first experiences or unfamiliar batches.
- Prepare the physical environment in advance: comfortable temperature, accessible water and light snacks, minimal stimulation, and a quiet space to retreat to if the experience becomes overwhelming.
- Keep a written note of substance name, dose, and time of ingestion visible — useful for the sitter and essential if emergency services are needed.
Set & Setting
Proscaline's 8–12 hour duration demands deliberate preparation. The full day should be free of obligations; fatigue or time pressure during the extended tail increases the likelihood of anxiety and irritability. A calm, familiar, private environment with a trusted sober companion is strongly recommended — especially given the compound's limited human data, which means individual responses are harder to predict than with well-characterized psychedelics.
Emotional state before dosing shapes the experience. Proscaline's somatic-emotional character amplifies both positive and negative affective states: warmth and contentment in favorable conditions, irritability and distress in unfavorable ones.
Aftercare & integration. The extended duration of proscaline means residual effects — emotional sensitivity, mild fatigue, altered dream patterns — may persist into the following day. Plan for a low-demand recovery day. Sleep may be disrupted the first night; this is expected and typically resolves without intervention.
Journaling or discussing the experience with a trusted person within the first few days helps consolidate insights and process difficult material. If distressing psychological content surfaces during the experience, integration-oriented therapy with a practitioner experienced in psychedelic contexts can be valuable. Persistent anxiety, depersonalization, or visual disturbances beyond a few days warrant professional consultation.
Recovery & Support
Proscaline does not produce physical dependence or withdrawal. However, repeated use of any psychedelic can become a pattern of avoidance or self-medication for underlying psychological distress. If psychedelic use is becoming compulsive, escalating, or interfering with daily functioning, support is available.
Peer support communities, harm reduction organizations, and therapists specializing in psychedelic integration can help. The Fireside Project (62-FIRESIDE / 623-473-7433) offers free peer support for people during or after psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety and transient confusion during a psychedelic experience are distressing but not emergencies. Seek immediate help if any of the following occur: chest pain or pounding heartbeat that does not subside, seizure activity, loss of consciousness, sustained panic with self-harm risk, or complete disconnection from reality with inability to recognize surroundings or people.
Immediate steps:
- Stay with the person. Speak calmly and simply.
- Move them to a quiet, low-stimulation environment if possible.
- If unconscious, place in the recovery position (on their side, airway clear).
- Call emergency services if symptoms are severe, worsening, or involve chest pain, seizure, or loss of consciousness.
- Do not restrain the person unless they are in immediate physical danger.
- Do not induce vomiting.
What to tell the dispatcher: Name the substance (proscaline, a psychedelic phenethylamine), the dose if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Proscaline occupies an ambiguous legal position in most jurisdictions. It is not individually scheduled by name in the majority of national drug control frameworks, but may be captured by structural analog provisions or generic phenethylamine clauses. Legal status should be independently verified for any specific jurisdiction, as analogue laws are subject to prosecutorial interpretation and evolving legislative frameworks.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A (Schedule 1) | Misuse of Drugs Act 1971, Schedule 2, Part I, paragraph 1(c): generic clause covering phenethylamine derivatives with ring alkoxy substitution[7] |
| United States | Not specifically scheduled (federal) | Mescaline is Schedule I (CSA). Proscaline is not individually listed. The Federal Analogue Act (21 U.S.C. §813) may apply if intended for human consumption, given structural similarity to mescaline |
| Canada | Not specifically scheduled | Mescaline is Schedule III (CDSA). Proscaline is not individually listed in the Controlled Drugs and Substances Act schedules |
| Australia | Uncertain | Mescaline is Schedule 9 (Prohibited Substance) under the Poisons Standard. Proscaline may be covered by analogue provisions but is not explicitly listed |
| Germany | Likely controlled | The Neue-psychoaktive-Stoffe-Gesetz (NpSG, 2016) uses structural analogue definitions that may cover proscaline[14] |
| Switzerland / Austria | Likely controlled | Phenethylamine analog scheduling provisions may capture proscaline under structural definitions[14] |
Analogue act considerations
In the United States, prosecution under the Federal Analogue Act requires demonstrating that proscaline is "substantially similar" in chemical structure and pharmacological effect to a Schedule I or II substance. Proscaline's direct structural derivation from mescaline — differing only in the 4-position alkoxy group — and its confirmed serotonin 2A receptor agonist activity[1] would likely satisfy both criteria. No published case law specifically addresses proscaline.
Frequently asked questions
How long does Proscaline last?
Total duration by route of administration — Oral: 8 – 12 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Proscaline?
Psychedex publishes a dosage table for Proscaline on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Proscaline?
The highest-severity documented interactions for Proscaline: MAOIs (Lethal), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Proscaline addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Proscaline: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT, DOx series, escaline. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcNichols DE (2018) Chemistry and Structure-Activity Relationships of Psychedelics. — Current Topics in Behavioral Neurosciences doi:10.1007/7854_2017_475
- [3]
- [4]
- [5] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6]
references
- [1]
- [2] ^abcNichols DE (2018) Chemistry and Structure-Activity Relationships of Psychedelics. — Current Topics in Behavioral Neurosciences doi:10.1007/7854_2017_475
- [3]
- [4]
- [5] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6]